-+ 0.00%
-+ 0.00%
-+ 0.00%

Prelude Therapeutics Q3 2026 net loss narrows 36% to $12.54 million

PUBT·11/16/2026 12:11:58
Listen to the news
Prelude Therapeutics Q3 2026 net loss narrows 36% to $12.54 million
  • Prelude Therapeutics’ third-quarter 2026 net loss narrowed 36% year over year to $12.54 million.
  • Revenue fell 13% year over year to $5.65 million, while research and development expenses dropped 32% to $14.83 million.
  • Cash, cash equivalents, restricted cash and marketable securities totaled $142.7 million at September 30; expected runway extends into second-quarter 2028.
  • PRT13722 began Phase 1 enrollment in fourth-quarter 2026, with initial proof-of-concept data expected in the second half of 2027.
  • A clinical collaboration with Lilly will evaluate PRT13722 alongside abemaciclib and imlunestrant in patients with HR+/HER2- breast cancer.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Prelude Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611160701PRIMZONEFULLFEED9877824) on November 16, 2026, and is solely responsible for the information contained therein.